Through 5 years, TAVI with a self-expanding valve provided clinical outcomes similar to those seen with surgery in an intermediate-risk population, according to continued follow-up of the SURTAVI trial.
Dr. Ketih Allen, surgeon at Saint Luke's Mid America Heart Institute, commented on the results of the SURTAVI Trial during a panel discussion that through 5 years, SURTAVI “continues to show that if you’re not going to get a mechanical valve, TAVR is . . . a really great option, and I think it should be first in the armamentarium.”
Read the full article and more about the SURTAVI Trail in tctMD: SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years.